Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis

George Dranitsaris,1 Lesley G Shane,2 Mark Crowther,3 Guillaume Feugere,4 Seth Woodruff2 1Health Economic and Outcomes Research, Augmentium Pharma Consulting Inc, Toronto, ON, Canada; 2Pfizer Inc, New York, NY, USA; 3McMaster University, Hamilton, ON, 4Pfizer Canada, Montreal, QC, Canada Background:...

Full description

Bibliographic Details
Main Authors: Dranitsaris G, Shane LG, Crowther M, Feugere G, Woodruff S
Format: Article
Language:English
Published: Dove Medical Press 2017-01-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Venous thromboembolism
cancer
recurrence
low molecular weight heparin
dalteparin
vitamin K antagonists
Online Access:https://www.dovepress.com/dalteparin-versus-vitamin-k-antagonists-for-the-prevention-of-recurren-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/dalteparin-versus-vitamin-k-antagonists-for-the-prevention-of-recurren-peer-reviewed-article-CEOR

Similar Items